Anti-Oxidant Treatment of Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Alzheimer's Disease
Interventions
DRUG

Vitamin E, Vitamin C, and Alpha-lipoic Acid

vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals

DRUG

Coenzyme Q

400 mg, compounded as a wafer, two wafers three times per day with meals

DRUG

Placebo capsules

one placebo capsule three times per day with meals

DRUG

Placebo wafers

two placebo wafers three times per day with meals

Trial Locations (13)

13210

Neurological Care of CNY, Syracuse

19104

University of Pennsylvania, Philadelphia

29406

Medical University of South Carolina, North Charleston

33140

Wien Center, Mount Sinai Medical Center, Miami Beach

40536

University of Kentucky, Lexington

44120

Case Western Reserve University, Cleveland

85724

University of Arizona, Tucson

90095

University of California, Los Angeles, Los Angeles

92037

University of California, San Diego, La Jolla

92697

University of California- Irvine, Irvine

97239

Oregon Health Sciences University, Portland

98108

University of Washington, Seattle

08855

University of Medicine and Dentistry of New Jersey, Piscataway

All Listed Sponsors
collaborator

Alzheimer's Disease Cooperative Study (ADCS)

OTHER

lead

National Institute on Aging (NIA)

NIH

NCT00117403 - Anti-Oxidant Treatment of Alzheimer's Disease | Biotech Hunter | Biotech Hunter